Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Co-ArgI-PEG · 1 trial · 1 indication
the dose level at which no more than 1/6 patients experiences dose-limiting toxicity
| Arm | Type | Description |
|---|---|---|
| AEB1102 Dose Escalation Cohort 1 | EXPERIMENTAL | 3 patients dosed at 0.01 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 2 | EXPERIMENTAL | 4 patients dosed at 0.02 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 3 | EXPERIMENTAL | 4 patients dosed at 0.04 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 4 | EXPERIMENTAL | 4 patients dosed at 0.08 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 5 | EXPERIMENTAL | 3 patients dosed at 0.12 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 6 | EXPERIMENTAL | 4 patients dosed at 0.18 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 7 | EXPERIMENTAL | 5 patients dosed at 0.27 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 8 | EXPERIMENTAL | 7 patients dosed at 0.40 mg/kg until MTD determined |
| AEB1102 Dose Escalation Cohort 9 | EXPERIMENTAL | 7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg |
| AEB1102 Expansion | EXPERIMENTAL | Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg |
| Name | Type | Description |
|---|---|---|
| Co-ArgI-PEG | DRUG | Administered IV |
Inclusion Criteria: For patients participating in any part of the trial: * has an advanced solid tumor previously treated with, or inability to tolerate, standard therapy for the disease, or for which a standard therapy does not exist, and as such is considered a candidate for Phase 1 treatment * ...
Co-ArgI-PEG is an investigational small molecule being developed for the treatment of advanced cancers. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy in patients with advanced solid tumors.
Co-ArgI-PEG is being developed by Spyre Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SYRE. The company is conducting clinical research to evaluate the drug's potential in oncology, specifically for patients with advanced cancers.
Co-ArgI-PEG is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 98 patients with advanced solid tumors. The drug is still investigational and has not received FDA approval, as it remains in the early stages of clinical testing.
Co-ArgI-PEG has one completed clinical trial registered under NCT02561234, titled "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors." This Phase 1 study enrolled 98 participants in the United States and evaluated the drug in patients with advanced cancers.
Yes, Co-ArgI-PEG is also known as AEB1102. The completed Phase 1 clinical trial NCT02561234, which evaluated the drug in patients with advanced solid tumors, used the name AEB1102 in its title. Both names refer to the same investigational small molecule being developed by Spyre Therapeutics.